Dose patient en neuroradiologie interventionnelle : bilan d’une enquête multicentrique

2011 ◽  
Vol 92 (12) ◽  
pp. 1101-1112 ◽  
Author(s):  
N. Kien ◽  
J.-L. Rehel ◽  
C. Étard ◽  
B. Aubert
Keyword(s):  
Dose Patient

scholarly journals Optimisation de la dose « patient » pour applications radiologiques spécifiques

2007 ◽  
Vol 42 (4) ◽  
pp. 551-563
Author(s):  
L. Struelens ◽  
F. Vanhavere ◽  
K. Smans
Keyword(s):  
Dose Patient

A Comparison of Variable-Dose Patient-Controlled Analgesia with Fixed-Dose Patient-Controlled Analgesia

1996 ◽  
Vol 83 (5) ◽  
pp. 1060-1064 ◽  
Author(s):  
David R. Love ◽  
Harry Owen ◽  
Anthony H. Ilsley ◽  
John L. Plummer ◽  
Russell M. Hawkins ◽  
...  
Keyword(s):  
Fixed Dose ◽  
Patient Controlled Analgesia ◽  
Dose Patient ◽  
Variable Dose

Optimisation de la dose patient en scanographie

2007 ◽  
Vol 88 (10) ◽  
pp. 1322
Author(s):  
I. Fitton ◽  
I. Khettab ◽  
G. Frija
Keyword(s):  
Dose Patient

scholarly journals Remifentanil Modifies the Relation of Electroencephalographic Spectral Changes and Clinical Endpoints in Propofol Anesthesia

2008 ◽  
Vol 109 (2) ◽  
pp. 198-205 ◽  
Author(s):  
Jukka Kortelainen ◽  
Miika Koskinen ◽  
Seppo Mustola ◽  
Tapio Seppänen
Keyword(s):  
Spectral Characteristics ◽  
High Dose ◽  
Verbal Command ◽  
Clinical Endpoints ◽  
Spectral Changes ◽  
Significant Difference ◽  
Anesthesia Monitoring ◽  
Patient Groups ◽  
Mutual Relations ◽  
Dose Patient

Background Depth-of-anesthesia monitoring with the electroencephalogram has become widely used in anesthesia practice. Generally, the methods presented are based on the spectral changes of the electroencephalogram. In this study, the authors evaluate the influence of remifentanil on the relation of timely occurrence of clinical endpoints and the spectral behavior of the electroencephalogram. Methods Twenty-seven patients scheduled to undergo a surgical procedure were randomly assigned to three groups. Patients blindly received equal volumes of saline or remifentanil (7.5 or 30 microg.kg.h) 1 min before induction of anesthesia with infusion of propofol (30 mg.kg.h). The occurrence of loss of counting, loss of obeying verbal command, and loss of reaction to tetanic stimulation was assessed. The electroencephalogram was recorded from electrode Fz referenced to the common average, and an iterative algorithm was applied to solve the underlying frequency progression pattern. The positions of the clinical endpoints on the pattern were analyzed. Results The administration of remifentanil during induction of anesthesia with propofol led to an earlier occurrence of the clinical endpoints on the frequency progression pattern. A significant difference (P < 0.05) was observed between the saline and high-dose patient groups in all three endpoints. The effect of remifentanil was proportional to the infusion rate. Conclusions The infusion of remifentanil during propofol anesthesia significantly modifies the mutual relations of the electroencephalographic spectral characteristics and the endpoints in a predictable and quantifiable manner. This finding suggests that the electroencephalographic phenomena and the endpoints may not be identical but rather to some extent separate manifestations of hypnotic drug effect.

Benzodiazepine Withdrawal

1981 ◽  
Vol 26 (2) ◽  
pp. 93-95 ◽  
Author(s):  
Y.D. Lapierre
Keyword(s):  
Drug Administration ◽  
Clinical Information ◽  
High Dose ◽  
Abrupt Cessation ◽  
Benzodiazepine Withdrawal ◽  
Withdrawal Syndromes ◽  
Dose Patient

This report summarizes pertinent biochemical, pharmacological and clinical information on the effects of abrupt cessation of benzodiazepine therapy. The need to discriminate between distress (anxiety) due to recurrences, rebound phenomena and withdrawal syndromes is emphasized. Although the longer-acting benzodiazepines are less likely to be followed by serious withdrawal reactions, abrupt cessation of drug administration in any dependent high-dose patient should be avoided.

Elevated International Normalized Ratio in a Patient Taking Warfarin and Mauby: A Case Report

2016 ◽  
Vol 30 (5) ◽  
pp. 567-570 ◽  
Author(s):  
Maria Sorbera ◽  
Tina Joseph ◽  
Robert V. DiGregorio
Keyword(s):  
Atrial Fibrillation ◽  
Case Report ◽  
Health Professionals ◽  
International Normalized Ratio ◽  
The Internet ◽  
Naranjo Algorithm ◽  
Folk Remedy ◽  
Caribbean Population ◽  
The Caribbean ◽  
Dose Patient

We describe a 70-year-old Haitian man who had been taking warfarin for 5 years for atrial fibrillation and pulmonary hypertension. This patient had his international normalized ratio (INR) checked in the pharmacist-run anticoagulation clinic and was followed monthly. Prior to the interaction, his INR was therapeutic for 5 months while taking warfarin 10.5 mg/d. The patient presented with an INR > 8.0. Patient held 4 days of warfarin and restarted on warfarin 8.5 mg/d. Two weeks later, his INR was 2.5. After continuing dose, patient presented 2 weeks later and INR was 4.8. Upon further questioning, the patient stated he recently began ingesting mauby. Mauby is a bitter dark liquid extracted from the bark of the mauby tree that is commonly used in the Caribbean population as a folk remedy with many health benefits. This case report illustrates that mauby may have a probable drug–herb interaction (Naranjo Algorithm Score of 6) when given with warfarin. There is a lack of published literature and unclear information on the Internet describing the interaction of mauby and warfarin. Health professionals should be cautious regarding interactions between warfarin and mauby until the interaction is fully elucidated.

Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing.

1989 ◽  
Vol 7 (11) ◽  
pp. 1741-1747 ◽  
Author(s):  
D R Strother ◽  
A Glynn-Barnhart ◽  
E Kovnar ◽  
R E Gregory ◽  
S B Murphy
Keyword(s):  
Clinical Experience ◽  
Initial Dose ◽  
Half Life ◽  
Interpatient Variability ◽  
Median Dose ◽  
Prior Therapy ◽  
Age Related ◽  
Dosage Guidelines ◽  
Serial Measurements ◽  
Dose Patient

Despite the clinical experience with Ommaya reservoir-facilitated intraventricular methotrexate (MTX) therapy, established age-related dosage guidelines do not exist. In an attempt to design such a schedule, 49 courses of intra-Ommaya MTX (median dose, 6 mg) administered to 12 patients were studied. Using a fluorescence polarized immunoassay (TDx; Abbott, Dallas, TX), the median peak intraventricular CSF MTX concentration (CSF [MTX]) was 423 mumol/L. Median CSF [MTX] at 24 hours was 4.6 mumol/L, and at 48 hours was 1.05 mumol/L. Median MTX half-life (t1/2) was 5.7 hours. A CSF [MTX] greater than 1 mumol/L was maintained for 24 hours in all but one course and for 48 hours in half of the courses. No correlations were found between MTX dose, patient age, [MTX], t1/2 or prior therapy. Considerable intra- and interpatient variability was seen in MTX disposition, emphasizing the need to monitor [MTX] with each course. A schedule for intraventricular MTX with an initial dose of 6 mg and supplemental doses of 6, 4, or 2 mg at 24 and 48 hours according to serial measurements of intraventricular [MTX] should be initiated to provide a minimum CSF [MTX] of 1 mumol/L for 72 hours.

Sign in / Sign up

Export Citation Format

Share Document